Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Pembrolizumab vs Treatment of Physician's Choice in Advanced Endometrial Cancer
NCT03517449Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2018
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of lenvatinib, pembrolizumab in endometrial carcinoma, sponsored by Eisai Co., Ltd.. Started Jun 2018; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT03517449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517449.